Trial Profile
Steady State Bioavailability of 2 Different Nevirapine Extended Release Formulations Compared to Steady State 400 mg of Viramune(R) (200 mg BID), in HIV-1 Infected Subjects, an Open Label, Non Randomised, Multidose and Multistage Parallel Group Study. (ERVIR)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Jul 2014
Price :
$35
*
At a glance
- Drugs Nevirapine (Primary)
- Indications HIV-1 infections
- Focus Pharmacokinetics
- Acronyms ERVIR
- Sponsors Boehringer Ingelheim
- 22 Jul 2014 New trial record